Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome

The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome was assessed. 32 patients were treated with eprosartan during 16 weeks. Dynamics of lipid peroxidation in plasma and thrombocytes, liquid part of blood and plate...

Full description

Saved in:

Bibliographic Details
Published in:	Klinicheskaia meditsina Vol. 86; no. 4; p. 19
Main Authors:	Simonenko, V B, Medvedev, I N, Kumova, T A
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2008
Subjects:	Acrylates - therapeutic use Angiotensin II Type 1 Receptor Blockers - therapeutic use Female Follow-Up Studies Humans Hypertension - blood Hypertension - complications Hypertension - drug therapy Imidazoles - therapeutic use Male Metabolic Syndrome - blood Metabolic Syndrome - complications Metabolic Syndrome - drug therapy Middle Aged Platelet Aggregation - drug effects Thiophenes - therapeutic use Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome was assessed. 32 patients were treated with eprosartan during 16 weeks. Dynamics of lipid peroxidation in plasma and thrombocytes, liquid part of blood and platelets antioxidant immunity, thrombocytes aggregative capacity were assessed. The results were processed using Student's test. The use of eprosartan in patients with arterial hypertension and metabolic syndrome has positive influence on peroxidation syndrome and optimizes thrombocytes aggregation.
ISSN:	0023-2149